JPH1112136A - Minoxidil-formulated aerosol - Google Patents
Minoxidil-formulated aerosolInfo
- Publication number
- JPH1112136A JPH1112136A JP9170811A JP17081197A JPH1112136A JP H1112136 A JPH1112136 A JP H1112136A JP 9170811 A JP9170811 A JP 9170811A JP 17081197 A JP17081197 A JP 17081197A JP H1112136 A JPH1112136 A JP H1112136A
- Authority
- JP
- Japan
- Prior art keywords
- aerosol
- minoxidil
- scalp
- stock solution
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 49
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960003632 minoxidil Drugs 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000009472 formulation Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 abstract description 17
- 210000004761 scalp Anatomy 0.000 abstract description 15
- 239000003380 propellant Substances 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 239000000243 solution Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 1
- -1 1.3-butylene glycol Chemical compound 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000003915 liquefied petroleum gas Substances 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000003273 male-pattern hair loss Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000003209 petroleum derivative Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- HPJYKMSFRBJOSW-JHSUYXJUSA-N Damsin Chemical compound C[C@H]1CC[C@H]2C(=C)C(=O)O[C@H]2[C@]2(C)C(=O)CC[C@@H]12 HPJYKMSFRBJOSW-JHSUYXJUSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000001599 crocus sativus l. flower extract Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229940076591 saffron extract Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術】本発明は有効成分としてミノキシ
ジルが配合された、頭皮へ該有効成分を確実に噴霧する
ことのできるエアゾール剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an aerosol formulation containing minoxidil as an active ingredient and capable of reliably spraying the active ingredient onto the scalp.
【0002】[0002]
【従来の技術】近年、高血圧症の治療薬として用いられ
てきた医薬であるミノキシジル(2,4−ジアミノ−6
−ピペリジノピリミジン−3−オキサイド)に多毛症が
副作用として認められたことから、発毛促進剤として男
性型脱毛、粗毛症への適用が検討されている。この男性
型脱毛、粗毛症への適用にあたっては、ミノキシジルの
本来の薬効である血圧降下作用が逆に好ましくない作用
として問題となるため、主に外用液剤やエアゾール剤に
よる頭皮への直接投与という方法または剤型の工夫によ
り、先の問題点を回避している。2. Description of the Related Art Minoxidil (2,4-diamino-6), a drug which has been used as a therapeutic agent for hypertension in recent years.
-Piperidinopyrimidine-3-oxide) was found to have hirsutism as a side effect, and its use as a hair growth-promoting agent for male pattern hair loss and hirsutism has been studied. When applied to male pattern hair loss and rosacea, the blood pressure lowering effect, which is the original medicinal effect of minoxidil, becomes a problem as an unfavorable effect. Therefore, a method of direct administration to the scalp mainly using an external solution or an aerosol. Alternatively, the above problem is avoided by devising a dosage form.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、外用液
剤では薬効の発現、副作用の抑制という面では効果はあ
ったものの、使用感の面や雑菌汚染の防止の点で必ずし
も満足できるものではない。また、エアゾール剤は簡便
性、無菌性に優れた特徴を持つものの、霧状となった有
効成分の吸入や大気中への飛散による損失等の問題を有
している。また、噴射性状を泡状としたフォーム剤も開
発されているが、毛髪に阻まれ有効成分が頭皮に到達し
にくい等の問題があり、発毛効果の面で十分なものでは
ない。このように、頭皮に確実に有効成分を提供できか
つ使用感に優れる剤型の開発が望まれていた。[0007] However, while the external liquid preparation has been effective in terms of the manifestation of medicinal effects and suppression of side effects, it is not always satisfactory in terms of feeling of use and prevention of bacterial contamination. In addition, although the aerosol is excellent in simplicity and sterility, it has problems such as inhalation of the atomized active ingredient and loss due to scattering into the atmosphere. Foams having a foaming property have also been developed, but have problems such as being blocked by the hair and making it difficult for the active ingredient to reach the scalp, and are not sufficient in terms of the hair growth effect. Thus, the development of a dosage form that can reliably provide an active ingredient to the scalp and has an excellent feeling upon use has been desired.
【0004】[0004]
【課題を解決するための手段】本発明者らはミノキシジ
ル配合育毛剤の開発に際し、エアゾール剤における噴射
性状を工夫することで、従来のエアゾール剤の特徴を保
持しつつ、ミノキシジルの拡散を抑え、かつ頭皮へのミ
ノキシジルの到達性が改善された発毛効果の優れるエア
ゾール剤を調製できることを見出し、更にその知見に基
づき本発明を完成した。 すなわち、本発明は噴射性状
がストリーム状或いはシャーベット状であることを特徴
とする、ミノキシジル配合エアゾール剤である。Means for Solving the Problems In developing a hair growth agent containing minoxidil, the present inventors devised the injection properties of the aerosol to suppress the diffusion of minoxidil while maintaining the characteristics of the conventional aerosol, In addition, the inventors have found that an aerosol preparation having an improved hair growth effect with improved accessibility of minoxidil to the scalp can be prepared, and the present invention has been completed based on the findings. That is, the present invention is an aerosol formulation containing minoxidil, characterized in that the jetting properties are stream-like or sherbet-like.
【0005】本発明における噴射性状がストリーム状で
あるエアゾール剤とは、エアゾール容器から噴射される
内容物が霧状となって大気中に拡散されることなく、内
容物が線状となって噴射されるエアゾール剤を言う。ま
た、噴射性状がシャーベット状であるエアゾール剤と
は、エアゾール容器から噴射される内容物が霧状となっ
て大気中に拡散されることなく、噴射時に内容物が冷却
されて粒子径の大きい塊状となるエアゾール剤を言う。In the present invention, the aerosol having a jetting property in a stream form means that the content jetted from an aerosol container does not become a mist and is diffused into the atmosphere, but the content becomes linear. Aerosol agent. An aerosol having a jetting property in the form of a sherbet means that the content sprayed from the aerosol container does not become a mist and is not diffused into the atmosphere, but the content is cooled at the time of spraying and a large particle size is obtained. Aerosol agent.
【0006】ストリーム状あるいはシャーベット状のエ
アゾール剤を用いてミノキシジルを頭皮に噴射する場
合、いずれの性状においても通常のエアゾール剤のよう
に内容物が霧状とならずミノキシジルの飛散が極めて少
ないため、大気中へのミノキシジルの損失等を著しく低
減することができる。また、物理的噴射圧が霧状のエア
ゾール剤に比べて高いので、有毛部であっても効果的に
ミノキシジルを頭皮に到達させることができる。When minoxidil is sprayed onto the scalp using a stream-type or sherbet-type aerosol, the contents are not mist-like and the scattering of minoxidil is extremely small as in a conventional aerosol, regardless of the properties. Minoxidil loss to the atmosphere can be significantly reduced. In addition, since the physical injection pressure is higher than that of the atomized aerosol, minoxidil can effectively reach the scalp even in the hairy part.
【0007】更に、霧状のエアゾール剤では得ることの
できない物理的圧力により頭皮を刺激することができ、
加えてシャーベット性状においては塗布部冷却によるリ
バウンド効果により、一時的に頭皮における血流量を増
加させることができる。このため、頭皮への到達率の低
い霧状またはフォーム状のエアゾール剤剤に比べては無
論のこと、ミノキシジルを直接頭皮に塗布した場合と比
べても、ミノキシジルの初期の経皮吸収速度の高まる事
が判明した。このことは、本発明のエアゾール剤が、従
来のミノキシジル配合外用剤に比べ、より発毛効果に優
れることを意味する。すなわち、本願発明のストリーム
状或いはシャーベット状のミノキシジル配合エアゾール
剤を用いれば、この一時的な血流量増加作用を頭皮のマ
ッサージ等を行わなくても容易に得られるのである。Further, the scalp can be stimulated by physical pressure which cannot be obtained with a nebulized aerosol,
In addition, in the sherbet property, the blood flow in the scalp can be temporarily increased due to the rebound effect by cooling the application portion. Therefore, the initial percutaneous absorption rate of minoxidil is increased compared to the case where minoxidil is directly applied to the scalp, not to mention the atomized or foam-type aerosol having a low rate of reaching the scalp. The thing turned out. This means that the aerosol of the present invention is more excellent in hair growth effect than the conventional external preparation containing minoxidil. That is, when the stream-type or sherbet-type aerosol composition containing minoxidil of the present invention is used, the effect of temporarily increasing the blood flow can be easily obtained without massaging the scalp.
【0008】[0008]
【発明の実施の形態】本発明におけるミノキシジルの配
合量は、原液中で0.1重量%以上とすることが望まし
い。0.1重量%を下回った場合、本発明の性状のエア
ゾール剤によって血流量が増加しても、ミノキシジルの
薬効が充分に発揮されない恐れがある。エアゾール剤の
噴射性状をストリーム状とするには、従来用いられてき
た如何なる方法をも用いることができる。例えば、エア
ゾール剤の一形態として用いられてきた原液と噴射剤が
同一室内に封入された形態では、原液と噴射剤の重量比
を重量比率を、原液:噴射剤が99.9:0.1〜4
0:60、より好ましくは99.5:0.5〜50:5
0に調節し、噴射の際に内容物がバルブハウジング内に
到達する流路を一経路とすれば良い。また、容器内が2
室に分割された2重構造容器を用いて原液と噴射剤を隔
絶し噴射する方法や、容器内に取り付けられたゴム製の
インナーバッグ内に原液を封入し、噴射剤を使用せずそ
のインナーバックの収縮力を利用し噴射する方法等を用
いてストリーム状とすることもできる。BEST MODE FOR CARRYING OUT THE INVENTION The amount of minoxidil in the present invention is desirably 0.1% by weight or more in a stock solution. If the amount is less than 0.1% by weight, the efficacy of minoxidil may not be sufficiently exerted even if the blood flow rate is increased by the aerosol of the present invention. In order to make the spray property of the aerosol agent into a stream, any conventionally used method can be used. For example, in a form in which a stock solution and a propellant, which have been used as one form of an aerosol, are sealed in the same chamber, the weight ratio of the stock solution and the propellant is the weight ratio, and the stock solution: propellant is 99.9: 0.1. ~ 4
0:60, more preferably 99.5: 0.5 to 50: 5
It may be adjusted to 0 and the flow path through which the contents reach the inside of the valve housing at the time of injection may be one path. The inside of the container is 2
A method in which a stock solution and a propellant are separated and sprayed using a double-structured container divided into chambers, and a stock solution is sealed in a rubber inner bag attached to the container, and the inner solution is used without using a propellant. It is also possible to form a stream using a method of injecting utilizing the contraction force of the bag.
【0009】また、噴射形状をシャーベット状とするに
は、従来用いられてきた如何なる方法をも用いることが
でき、例えば、水、低級アルコール、特定の界面活性剤
を配合する方法(特開平4−103526号公報記載の
発明)などを挙げることができる。 本発明のエアゾー
ル剤の噴射圧力供給物としては、通常用いられる液化ガ
ス、例えば液化石油ガスやジメチルエーテル、フロンの
他、圧縮ガス、例えば窒素、酸素、炭酸ガス、空気等を
用いることができる。また、先に述べたようにエアゾー
ル容器内のゴム製インナーバッグ等のような、ガス圧以
外の物理的圧力を供給する構造を用いても良く、結果と
して噴射性状がストリーム状或いはシャーベット状とな
れば本発明の効果は得られる。Further, in order to form the jetting shape into a sherbet shape, any conventionally used method can be used. For example, a method in which water, a lower alcohol and a specific surfactant are blended (Japanese Unexamined Patent Publication No. No. 103526). As the injection pressure supply of the aerosol agent of the present invention, a commonly used liquefied gas such as liquefied petroleum gas, dimethyl ether, and chlorofluorocarbon, as well as a compressed gas such as nitrogen, oxygen, carbon dioxide, and air can be used. Further, as described above, a structure for supplying a physical pressure other than the gas pressure, such as a rubber inner bag in an aerosol container, may be used, and as a result, the jetting property becomes a stream-like or sherbet-like. Thus, the effects of the present invention can be obtained.
【0010】本発明のエアゾール剤には、香料、色素の
他、ミノキシジルの薬効を補助しまたはその他の薬効を
追加することを目的として、以下のような成分を適時添
加することができる。The following components can be added to the aerosol of the present invention at appropriate times in addition to flavors and pigments for the purpose of assisting the medicinal effect of minoxidil or adding other medicinal effects.
【0011】血管拡張剤 塩化カルプロニウム、ニコチン酸ベンジル、センブリ抽
出物、オタネニンジンエキス、ビタミンEアセテート、
トウガラシチンキ等 副腎皮質ホルモン 酢酸ヒドロコルチゾン、酪酸プロピオン酸ヒドロコルチ
ゾン等 角質軟化剤 尿素、サリチル酸等 保湿剤 ヒアルロン酸ナトリウム、コンドロイチン硫酸、冬虫夏
草抽出物、サフラン抽出物等 抗ヒスタミン薬 塩酸ジフェンヒドラミン、サリチル酸ジフェンヒドラミ
ン、ジフェンヒドラミン、マレイン酸クロルフェニラミ
ン 抗炎症薬 サリチル酸メチル、サリチル酸グリコール、インドメタ
シン、イブプロフェン、フルルビプロフェン、ジクロフ
ェナク、フェルビナク、ケトプロフェン、グリチルリチ
ン酸ジカリウム、グリチルレチン酸、アズレン誘導体等 殺菌剤 グルコン酸クロルヘキシジン、イソプロピルメチルフェ
ノール、第4級アンモニウム塩、ヒノキチオール等 抗酸化剤 ジブチルヒドロキシトルエン、イソプロピルガレート等 清涼化剤 メントール、ハッカ油、カンフル等 また、これらの各種成分の配合に応じた製剤化に利用可
能な成分としては以下のようなものが挙げられる。Vasodilator carpronium chloride, benzyl nicotinate, assembly extract, panax ginseng extract, vitamin E acetate,
Pepper tincture etc.Adrenal corticosteroids Hydrocortisone acetate, Hydrocortisone butyrate propionate, etc.Keratin softeners Urea, salicylic acid, etc.Humectants Sodium hyaluronate, chondroitin sulfate, Cordyceps sinensis extract, saffron extract, etc. Chlorpheniramine acid Anti-inflammatory drug Methyl salicylate, glycol salicylate, indomethacin, ibuprofen, flurbiprofen, diclofenac, felbinac, ketoprofen, dipotassium glycyrrhizinate, glycyrrhetinic acid, azulene derivative, etc. fungicide chlorhexidine gluconate, isopropylmethylphenol, No. 4 Grade ammonium salt, hinokitiol, etc. Antioxidant dibutylhydroxytol Down, isopropyl gallate, etc. fresheners menthol, peppermint oil, camphor As the component available for formulation in accordance with the formulation of these various ingredients include the following.
【0012】基剤 水、メタノール、エタノール、変性エタノール、イソプ
ロピルアルコール等の低級アルコール 溶解補助剤 アジピン酸ジイソプロピル、ミリスチン酸イソプロピ
ル、1.3−ブチレングリコール、プロピレングリコー
ル、ポリエチレングリコール、グリセリン、中鎖脂肪酸
トリグリセリド、脂肪酸エステル類、各種植物油、各種
動物油、多価アルコール脂肪酸エステル、アルキルグリ
セリルエーテル、炭化水素類、乳酸、水酸化ナトリウム
等 界面活性剤 ソルビタン脂肪酸エステル、グリセリン脂肪酸エステ
ル、ポリグリセリン脂肪酸エステル、プロピレングリコ
ール脂肪酸エステル、、ポリオキシエチレンソルビタン
脂肪酸エステル、ポリオキシエチレンソルビット脂肪酸
エステル、ポリオキシエチレングリセリン脂肪酸エステ
ル、ポリエチレングリコール脂肪酸エステル、ポリオキ
シエチレンアルキルエーテル、ポリオキシエチレンポリ
オキシプロピレンアルキルエーテル、ポリオキシエチレ
ンアルキルフェニルエーテル、ポリオキシエチレン硬化
ヒマシ油、ポリオキシエチレンヒマシ油、ポリオキシエ
チレンミツロウ誘導体、ポリオキシエチレンラノリン誘
導体、ポリオキシエチレンアルキルアミド、ポリオキシ
エチレンアルキルアミン、レシチン誘導体、高分子乳化
剤 乳化安定剤(高級アルコール等)、ゲル化剤(高分子
等)、粘着剤等Base Water, lower alcohols such as methanol, ethanol, denatured ethanol and isopropyl alcohol Solubilizers Diisopropyl adipate, isopropyl myristate, 1.3-butylene glycol, propylene glycol, polyethylene glycol, glycerin, medium chain fatty acid triglyceride , Fatty acid esters, various vegetable oils, various animal oils, polyhydric alcohol fatty acid esters, alkyl glyceryl ethers, hydrocarbons, lactic acid, sodium hydroxide, etc. Surfactants sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, propylene glycol fatty acids Ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene glycerin fatty acid Stele, polyethylene glycol fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene beeswax derivative, polyoxy Ethylene lanolin derivative, polyoxyethylene alkylamide, polyoxyethylene alkylamine, lecithin derivative, polymer emulsifier Emulsion stabilizer (higher alcohol etc.), gelling agent (polymer etc.), adhesive etc.
【0013】[0013]
【発明の効果】本発明のエアゾール剤によれば、ミノキ
シジルの飛散による損失を抑え、ミノキシジルが頭皮に
効率的に到達させることができる。また、投与部位の血
流量を増加させることでミノキシジルの初期の経皮吸収
速度を高めることができる。According to the aerosol of the present invention, the loss due to the scattering of minoxidil can be suppressed and the minoxidil can efficiently reach the scalp. In addition, the initial percutaneous absorption rate of minoxidil can be increased by increasing the blood flow at the administration site.
【0014】[0014]
<実施例1> ストリーム状エアゾール ミノキシジル1g、プロピレングリコール10g、エタ
ノール89gを充分に混和したエアゾール原液100g
を調製し、この原液55gをエアゾール用耐圧容器に充
填し、更に噴射剤としてジメチルエーテル45gを充填
した後、バルブ、アクチュエーターを装着し、ストリー
ム状エアゾール製品とした。<Example 1> Stream aerosol 100 g of aerosol stock solution sufficiently mixed with 1 g of minoxidil, 10 g of propylene glycol, and 89 g of ethanol.
55 g of this stock solution was charged into a pressure-resistant container for aerosol, and further charged with 45 g of dimethyl ether as a propellant, and then a valve and an actuator were attached to obtain a stream aerosol product.
【0015】<実施例2> シャーベット状エアゾール ミノキシジル2g、ポリエチレングリコール5g、ミリ
スチン酸イソプロピル2g、ステアリルアルコール3
g、ポリオキシエチレンアルキルエーテル3g、エタノ
ール50g、精製水35gを充分に混和してエアゾール
原液100gを調製し、この原液液30gをエアゾール
用耐圧容器に充填し、更に噴射剤として液化石油ガス1
5gとジメチルエーテル55gを充填した後、バルブ、
アクチュエーターを装着し、シャーベット状エアゾール
製品とした。Example 2 Sherbet-like aerosol Minoxidil 2 g, polyethylene glycol 5 g, isopropyl myristate 2 g, stearyl alcohol 3
g, 3 g of polyoxyethylene alkyl ether, 50 g of ethanol and 35 g of purified water are sufficiently mixed to prepare 100 g of an aerosol stock solution, 30 g of this stock solution is filled in a pressure-resistant container for aerosol, and liquefied petroleum gas 1 is further used as a propellant.
After filling with 5 g and 55 g of dimethyl ether, a valve,
An actuator was mounted to obtain a sherbet-like aerosol product.
【0016】<実施例3> ストリーム状エアゾール 下記の成分を充分に混和してエアゾール原液を調製し
た。<Example 3> Stream aerosol The following components were sufficiently mixed to prepare an aerosol stock solution.
【0017】 ミノキシジル 1.0g ヒノキチオール 0.01g グリチルレチン酸 0.2g ポリ(オキシエチレン・オキシプロピレン) メチルポリシロキサン共重合体 0.4g 1,3−ブチレングリコール 1.0g ポリオキシエチレン硬化ヒマシ油 0.5g パントテニールエチルエーテル 0.2g L−メントール 0.5g DL−カンフル 0.1g ハッカ油 0.1g ユーカリ油 0.05g チョウジ油 0.001g ホホバアルコール 0.1g センブリエキス 0.05g ニンジンエキス 0.03g エタノール 50.0mL 精製水 全100gとする この原液50gをエアゾール用耐圧容器に充填し、更に
噴射剤として液化石油ガス10g、ジメチルエーテル4
0gを充填した後、バルブ、アクチュエーターを装着
し、ストリーム状エアゾール製品とした。Minoxidil 1.0 g Hinokitiol 0.01 g Glycyrrhetinic acid 0.2 g Poly (oxyethylene / oxypropylene) methylpolysiloxane copolymer 0.4 g 1,3-butylene glycol 1.0 g Polyoxyethylene hydrogenated castor oil 5 g Pantothenyl ethyl ether 0.2 g L-menthol 0.5 g DL-camphor 0.1 g peppermint oil 0.1 g eucalyptus oil 0.05 g clove oil 0.001 g jojoba alcohol 0.1 g assembly extract 0.05 g carrot extract 0.03 g Ethanol 50.0 mL Purified water Total 100 g Fill 50 g of this undiluted solution into a pressure-resistant container for aerosol, and further liquefy petroleum gas 10 g as a propellant and dimethyl ether 4
After filling with 0 g, a valve and an actuator were attached to obtain a stream aerosol product.
【0018】<比較例1>ミノキシジル1g、プロピレ
ングリコール10g、エタノール89gを均一に混和
し、外用液剤100gを調製した。<Comparative Example 1> 1 g of minoxidil, 10 g of propylene glycol and 89 g of ethanol were uniformly mixed to prepare 100 g of a liquid preparation for external use.
【0019】<比較例2>ミノキシジル1g、プロピレ
ングリコール10g、エタノール89gを充分に混和し
てエアゾール原液100gを調製し、この原液30gを
エアゾール用耐圧容器に充填し、更に噴射剤として液化
石油ガス30gとジメチルエーテル40gを充填した
後、バルブ、アクチュエーターを装着し、霧状エアゾー
ル剤を調製した。<Comparative Example 2> 1 g of minoxidil, 10 g of propylene glycol, and 89 g of ethanol were sufficiently mixed to prepare 100 g of an aerosol stock solution, 30 g of this stock solution was filled in a pressure-resistant container for aerosol, and 30 g of liquefied petroleum gas as a propellant. And 40 g of dimethyl ether, and then a valve and an actuator were attached to prepare a mist aerosol.
【0020】<比較例3>ミノキシジル1g、プロピレ
ングリコール5g、エタノール5g、スクワラン4g、
セタノール1.5g、グリセリンモノステアレート1
g、ポリオキシエチレンソルビタンモノオレエート3
g、ソルビタンモノオレエート1.5g、ポリオキシエ
チレンラノリン2g、精製水76gを充分に乳化混和し
てエアゾール原液100gを調製し、この原液95gを
エアゾール用耐圧容器に充填し、更に噴射剤として液化
石油ガス5gを充填した後、バルブ、スパウトを装着
し、泡状エアゾール製品(フォーム剤)とした。Comparative Example 3 1 g of minoxidil, 5 g of propylene glycol, 5 g of ethanol, 4 g of squalane,
1.5 g of cetanol, glycerin monostearate 1
g, polyoxyethylene sorbitan monooleate 3
g, 1.5 g of sorbitan monooleate, 2 g of polyoxyethylene lanolin and 76 g of purified water are sufficiently emulsified and mixed to prepare 100 g of an aerosol stock solution. 95 g of this stock solution is filled in a pressure-resistant container for aerosol, and further liquefied as a propellant. After filling with 5 g of petroleum gas, a valve and a spout were attached to obtain a foamed aerosol product (foam).
【0021】<試験例1>実施例1〜3及び比較例1を
用い、被験者30名に使用感試験を行った。投与しやす
さ、感覚等使用感には多岐に及ぶ項目があり、その個人
によっても重視する項目が異なるため、質問事項は「使
用感はどうか」の1項目とし、7段階評価で評価をして
もらった。評点は、極めて良い−7点、良い−6点、や
や良い−5点、普通−4点、やや悪い−3点、悪い−2
点、極めて悪い−1点とし、6点以上の評価した人数で
評価した。<Test Example 1> Using Examples 1 to 3 and Comparative Example 1, 30 subjects were subjected to a usability test. There are a wide variety of items such as ease of administration and sensation, and the items to be emphasized differ depending on the individual. I got it. The rating is extremely good -7 points, good -6 points, fairly good -5 points, ordinary -4 points, slightly bad -3 points, bad -2.
Points, extremely bad-1 point, and evaluated by the number of people who scored 6 points or more.
【0022】結果を表1に示す。The results are shown in Table 1.
【0023】[0023]
【表1】 [Table 1]
【0024】<試験例2>実施例1〜3及び比較例2、
3を検体とし、ウイスター系ラット(7〜10週齢、n
=3、計15匹)の腹部に5cmの距離から検体を約3
秒間、噴射した。噴射10分後、腹部をシェーバーにて
除毛し、露出した腹部皮膚をアルコール含有脱脂綿にて
清拭した。その脱脂綿及び噴射後の検体のミノキシジル
を定量し、腹部皮膚に到達したミノキシジル量と噴射さ
れたミノキシジル量を求めた。<Test Example 2> Examples 1-3 and Comparative Example 2,
3 as a sample, Wistar rats (7-10 weeks old, n
= 3, a total of 15 animals).
Sprayed for seconds. Ten minutes after the injection, the abdomen was shaved with a shaver, and the exposed abdominal skin was wiped with alcohol-containing absorbent cotton. The amount of minoxidil in the absorbent cotton and the sample after the injection was quantified, and the amount of minoxidil reaching the abdominal skin and the amount of the minoxidil injected were determined.
【0025】結果を表2に示す。The results are shown in Table 2.
【0026】[0026]
【表2】 [Table 2]
【0027】<試験例3>実施例1〜3及び比較例1、
2を検体とし、男性被験者10名の右前腕部に投与し、
血流量の変化率をレーザードップラー式血流計(PeriFl
ux System 4000:日本ユーロテック株式会社製)にて測
定した。被験者は定常状態の血流量とするため恒温恒湿
(温度23℃、相対湿度60%)に保たれた室内に入室
した後、上半身の衣服を脱衣し待機させた。被験者が脱
衣1時間後、その室内にて血流量が定常状態になった事
を確認し、測定を開始した。なおミノキシジル自体が血
流量に影響を及ぼすため、薬剤の影響がない様、測定時
間は30分間で終了し、その間の血流量の変化率で評価
した。評価は血流量が20%以上上昇した場合を○、1
0%以上上昇した場合を△、血流量の上昇が10%未満
である場合を×として表す。結果を表3に示す。<Test Example 3> Examples 1 to 3 and Comparative Example 1
2 as a sample, and administered to the right forearm of 10 male subjects,
Laser Doppler blood flow meter (PeriFl
ux System 4000: manufactured by Eurotech Japan Ltd.). The subject entered a room maintained at a constant temperature and humidity (temperature 23 ° C., relative humidity 60%) in order to obtain a steady state blood flow, then undressed his upper body and waited. One hour after the subject undressed, it was confirmed that the blood flow was in a steady state in the room, and measurement was started. In addition, since minoxidil itself affects the blood flow, the measurement time was completed in 30 minutes so that there was no influence of the drug, and evaluation was made based on the change rate of the blood flow during that time. The evaluation was made when the blood flow increased by 20% or more.
The case where the increase is 0% or more is represented by Δ, and the case where the increase in blood flow is less than 10% is represented by x. Table 3 shows the results.
【0028】[0028]
【表3】 [Table 3]
【0029】試験例1、試験例2、試験例3の結果よ
り、本発明は目的とする部位に確実に到達し、血流量が
増加するため、ミノキシジルの副作用を抑制し、併用効
果が期待でき、更に使用感に優れていることが確認され
た。From the results of Test Example 1, Test Example 2 and Test Example 3, the present invention reliably reaches the target site and increases the blood flow, so that the side effect of minoxidil can be suppressed and the combined effect can be expected. It was further confirmed that the feeling of use was excellent.
Claims (1)
ット状であることを特徴とする、ミノキシジル配合エア
ゾール剤。1. An aerosol formulation containing minoxidil, characterized in that the spraying property is a stream or sherbet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9170811A JPH1112136A (en) | 1997-06-27 | 1997-06-27 | Minoxidil-formulated aerosol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9170811A JPH1112136A (en) | 1997-06-27 | 1997-06-27 | Minoxidil-formulated aerosol |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH1112136A true JPH1112136A (en) | 1999-01-19 |
Family
ID=15911783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9170811A Pending JPH1112136A (en) | 1997-06-27 | 1997-06-27 | Minoxidil-formulated aerosol |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH1112136A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030844A1 (en) * | 2001-10-04 | 2003-04-17 | Taisho Pharmaceutical Co., Ltd. | Long-acting hair growth stimulant preparations |
JP2005126347A (en) * | 2003-10-22 | 2005-05-19 | Taisho Pharmaceut Co Ltd | Aerosol composition for hair |
JP2006265137A (en) * | 2005-03-23 | 2006-10-05 | Daizo:Kk | Emulsion aerosol composition |
JP2006342090A (en) * | 2005-06-08 | 2006-12-21 | Taisho Pharmaceut Co Ltd | Aerosol |
JP2007044155A (en) * | 2005-08-08 | 2007-02-22 | Shiseido Co Ltd | Container using rubber material reducing coloration etc. of minoxidil preparation |
JP2009173561A (en) * | 2008-01-22 | 2009-08-06 | Daizo:Kk | Aerosol composition |
JP2011051980A (en) * | 2009-08-05 | 2011-03-17 | Taisho Pharmaceutical Co Ltd | Hair-growing agent |
JP2013001682A (en) * | 2011-06-17 | 2013-01-07 | Mandom Corp | Aerosol composition and injection type aerosol agent |
WO2014087421A2 (en) | 2012-12-04 | 2014-06-12 | Dow Corning India Private Limited | Stable hydrophilic medium-soluble composition and the use thereof |
JP2017186309A (en) * | 2016-03-30 | 2017-10-12 | 大正製薬株式会社 | Aerosol agent |
JP2017186310A (en) * | 2016-03-30 | 2017-10-12 | 大正製薬株式会社 | Aerosol agent |
WO2020013179A1 (en) * | 2018-07-09 | 2020-01-16 | 国立大学法人九州大学 | Percutaneous absorption composition with controlled release of minoxidil |
JP6871661B1 (en) * | 2020-10-01 | 2021-05-12 | 富士産業株式会社 | Hair growth method and cooling hair growth agent |
WO2021132529A1 (en) * | 2019-12-27 | 2021-07-01 | 国立大学法人九州大学 | Water-containing transdermally absorptive composition |
-
1997
- 1997-06-27 JP JP9170811A patent/JPH1112136A/en active Pending
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003030844A1 (en) * | 2001-10-04 | 2003-04-17 | Taisho Pharmaceutical Co., Ltd. | Long-acting hair growth stimulant preparations |
JP2005126347A (en) * | 2003-10-22 | 2005-05-19 | Taisho Pharmaceut Co Ltd | Aerosol composition for hair |
JP2006265137A (en) * | 2005-03-23 | 2006-10-05 | Daizo:Kk | Emulsion aerosol composition |
JP2006342090A (en) * | 2005-06-08 | 2006-12-21 | Taisho Pharmaceut Co Ltd | Aerosol |
JP2007044155A (en) * | 2005-08-08 | 2007-02-22 | Shiseido Co Ltd | Container using rubber material reducing coloration etc. of minoxidil preparation |
JP4592531B2 (en) * | 2005-08-08 | 2010-12-01 | 株式会社資生堂 | Aerosol container using rubber material to reduce coloring of minoxidil formulation |
JP2009173561A (en) * | 2008-01-22 | 2009-08-06 | Daizo:Kk | Aerosol composition |
JP2011051980A (en) * | 2009-08-05 | 2011-03-17 | Taisho Pharmaceutical Co Ltd | Hair-growing agent |
JP2013001682A (en) * | 2011-06-17 | 2013-01-07 | Mandom Corp | Aerosol composition and injection type aerosol agent |
WO2014087421A2 (en) | 2012-12-04 | 2014-06-12 | Dow Corning India Private Limited | Stable hydrophilic medium-soluble composition and the use thereof |
JP2017186309A (en) * | 2016-03-30 | 2017-10-12 | 大正製薬株式会社 | Aerosol agent |
JP2017186310A (en) * | 2016-03-30 | 2017-10-12 | 大正製薬株式会社 | Aerosol agent |
WO2020013179A1 (en) * | 2018-07-09 | 2020-01-16 | 国立大学法人九州大学 | Percutaneous absorption composition with controlled release of minoxidil |
WO2021132529A1 (en) * | 2019-12-27 | 2021-07-01 | 国立大学法人九州大学 | Water-containing transdermally absorptive composition |
JP6871661B1 (en) * | 2020-10-01 | 2021-05-12 | 富士産業株式会社 | Hair growth method and cooling hair growth agent |
JP2022059270A (en) * | 2020-10-01 | 2022-04-13 | 富士産業株式会社 | Hair growth method and hair growth agent for cooling |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101141220B1 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
EP2614815B1 (en) | Foamable aerosol composition | |
AU2021203466B2 (en) | External composition for screen foamers | |
JPH1112136A (en) | Minoxidil-formulated aerosol | |
JP3558393B2 (en) | Foamable aerosol composition | |
CA2567742A1 (en) | Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase | |
TW200902084A (en) | Topical composition | |
JPS6347684B2 (en) | ||
WO1998032417A1 (en) | Persistent hair tonic | |
BR112018073118B1 (en) | FOAMING FORMULATION, METHOD FOR PREPARING A FOAMABLE FORMULATION, AND PRESSURIZED PACKAGING | |
AU2005253734B2 (en) | Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase | |
JPH07112984B2 (en) | Foam aerosol formulation | |
JPWO2002083321A1 (en) | Aerosol products | |
JPH11349451A (en) | Hair grower | |
JP4450545B2 (en) | Aerosol formulation | |
JPS6254784A (en) | Aerosol composition | |
EP0440249A2 (en) | Ethanolamine for the treatment of keloid | |
JPWO2020138403A1 (en) | External composition for skin and aerosol | |
JP2003012501A (en) | Antipruritic aerosol preparation | |
JP4176859B2 (en) | Aerosol formulation | |
JP2001172170A (en) | Aerosol composition | |
JP2004026737A (en) | Liquid composition for aerosol preparation | |
JPH01305023A (en) | Rapidly breakable foaming aerosol composition | |
JPH1149665A (en) | Anti-inflammatory/analgesic composition and aerosol product using the same | |
RU2093146C1 (en) | Liquid self-foaming pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040603 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041210 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050524 |